NTLA241115P12500
- 0.18
- 0.000.00%
Intellia Therapeutics Newsroom
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Truist Financial Initiates a Buy Rating on Intellia Therapeutics (NTLA)
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $95
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $54
Intellia Therapeutics (NTLA) Receives a Buy From RBC Capital
Intellia Therapeutics Analyst Ratings
Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Intellia Therapeutics Is Maintained at Buy by Stifel
Truist Financial Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
JP Morgan Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Intellia Therapeutics Analyst Ratings